Floatz logo

Methylnaltrexone

Pancreatic Neoplasm

Bausch Health Americas, Inc.UNKNOWNPhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
59/ 100

Competitive context

377 Active assets in the Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
Cis-Diamminedichloroplatinum Ii
Taiho Oncology, Inc.
Phase 3BB
Xaliplatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Fluorouracilum
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Methylnaltrexone is also rated in:

opioid-induced constipationDormant
B
Indicative · Phase 3
61 / 100
View asset →
chronic pain syndromeActive
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →